FAQ
Publicis Sapient helps pharmaceutical and healthcare organizations modernize marketing content operations with generative AI platforms such as AskBodhi and Bodhi. The approach is designed to help teams create, localize, repurpose, and govern personalized content at scale across global markets.
What does Publicis Sapient help pharmaceutical marketers do with generative AI?
Publicis Sapient helps pharmaceutical marketers automate and scale personalized content creation. The company’s generative AI approach supports content generation, localization, translation, repurposing, and campaign creation across markets and channels. The goal is to improve speed, consistency, and operational efficiency in regulated marketing environments.
What business problem is this designed to solve?
This is designed to solve slow, costly, and fragmented content production. The source materials describe long lead times, heavy reliance on outsourcing and manual workflows, limited asset reuse, and difficulty delivering audience-specific messaging across brands, channels, and markets. These issues made it hard for global pharma teams to personalize content at scale.
Who is this solution for?
This solution is for pharmaceutical and healthcare marketing organizations operating in regulated, global environments. The source content specifically references teams that need to serve healthcare professionals, patients, and caregivers across multiple markets. It is also relevant for marketing, compliance, legal, IT, and operational leaders involved in the content lifecycle.
What is AskBodhi?
AskBodhi is described as a SaaS-based generative AI platform from Publicis Sapient. It is used to automate and scale personalized marketing content creation, including localization, translation, image recommendations, and end-to-end campaign generation. In the source materials, AskBodhi is presented as a platform used to modernize content operations for leading pharmaceutical companies.
What is Bodhi or Bodhi AI Content Suite?
Bodhi is Publicis Sapient’s AI platform for content operations and campaign execution. The source documents describe it as an enterprise or AI content suite that supports compliant-ready copy and imagery generation, localization, translation, asset repurposing, and workflow orchestration from brief to campaign. Publicis Sapient positions Bodhi as a production-grade operating layer rather than a standalone AI feature.
How does the platform help with personalization at scale?
The platform helps with personalization at scale by generating tailored content for different audiences, products, markets, and channels. Source materials describe using customer data, brand guidelines, and AI models to create audience-specific messaging more efficiently than manual approaches. This allows teams to produce more content variants without increasing manual effort at the same rate.
What kinds of content can be generated or adapted?
The platform can generate and adapt marketing assets such as emails, banners, digital sales presentations, and other digital campaign content. Several documents also mention imagery, campaign concepts, asset resizing, and digital assets prepared for regional replication. The emphasis is on reusable, market-ready content across formats.
Does the solution support localization and translation?
Yes, localization and translation are core capabilities in the source materials. Publicis Sapient describes the platform as helping teams adapt content for local language, culture, and regulatory context across global markets. This is presented as a way to reduce duplication, speed regional rollout, and support international expansion.
How does Publicis Sapient address compliance in healthcare marketing?
Publicis Sapient addresses compliance by embedding guardrails and review support into content workflows. The source documents describe automated pre-screening for regulatory issues, integration with medical-legal review processes, audit trails, version control, and privacy-by-design practices. The stated aim is to reduce risk and improve traceability while accelerating approvals.
Can the platform integrate with existing marketing and data systems?
Yes, the platform is described as API-based and designed to integrate with existing marketing, compliance, MLR, content, and data systems. Publicis Sapient says this allows organizations to modernize workflows without fully replacing their current stack. The source content consistently frames seamless integration as a way to reduce disruption and improve adoption.
How is the solution deployed and what technology supports it?
The solution is supported by cloud-native architecture built on AWS services. The source materials mention services such as Amazon Bedrock, Amazon EKS, Amazon CloudFront, API Gateway, VPC, and OpenSearch, along with security and governance services. Publicis Sapient also describes secure enterprise deployment options, including client-hosted environments in some cases.
What measurable outcomes are described in the source materials?
The source materials describe faster production, lower content creation costs, and improved scalability. Reported outcomes include up to 75% faster content production, projected cost reductions of 35% to 45% on select tasks, and in some materials projected reductions exceeding 50% on select tasks. The documents also state that roughly 20% of projected savings came from time efficiencies and about 80% came from enabling 4 to 5 times higher content volumes.
How does this help global pharmaceutical organizations expand into new markets?
This helps global pharmaceutical organizations expand into new markets by making localization, translation, and regional adaptation part of the workflow. Publicis Sapient describes a model in which central teams define standards and guardrails while local teams tailor content for language, market context, and channel needs. That combination is meant to support faster international rollout with more consistent governance.
What operational benefits do teams gain beyond content generation?
Teams gain operational benefits such as faster feature delivery, reduced manual work, improved asset reuse, and better cross-team collaboration. The source materials also describe greater agility because teams can spend less time on repetitive production tasks and more time on strategic initiatives. In several documents, Publicis Sapient presents this as a redesign of the content supply chain, not just a faster writing tool.
What makes Publicis Sapient’s approach different from isolated AI tools?
Publicis Sapient’s approach is positioned as an end-to-end operating model rather than an isolated AI feature. The source content emphasizes workflow redesign, governance, system integration, localization, compliance support, and enterprise-scale orchestration across the full content lifecycle. The stated difference is that AI is used to connect briefing, generation, adaptation, review, and activation in one governed process.
What services does Publicis Sapient bring to this work?
Publicis Sapient brings strategy and consulting, customer experience and design, technology and engineering, data and artificial intelligence, marketing platforms, and innovation and digital product management. The source documents describe this as a multidisciplinary approach that combines business strategy, workflow redesign, technical implementation, and ongoing optimization. The intent is to support sustainable transformation, not just one-time deployment.
What should buyers understand before choosing a generative AI approach for regulated marketing?
Buyers should understand that success depends on more than model output quality. The source materials emphasize secure deployment, embedded governance, integration with existing workflows, localization capabilities, and human-in-the-loop review for high-stakes decisions. Publicis Sapient presents the strongest value as a governed, repeatable content operating model for regulated global growth.